Loading
PDBj
MenuPDBj@FacebookPDBj@TwitterPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

6H5W

Crystal structure of human Angiotensin-1 converting enzyme C-domain in complex with Omapatrilat.

Summary for 6H5W
Entry DOI10.2210/pdb6h5w/pdb
DescriptorAngiotensin-converting enzyme, 1,2-ETHANEDIOL, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, ... (11 entities in total)
Functional Keywordsangiotensin-1 converting enzyme, ace inhibitor, omapatrilat, vasopeptidase inhibitor, hydrolase
Biological sourceHomo sapiens (Human)
Total number of polymer chains1
Total formula weight71725.56
Authors
Cozier, G.E.,Acharya, K.R. (deposition date: 2018-07-25, release date: 2018-11-07, Last modification date: 2024-01-17)
Primary citationCozier, G.E.,Arendse, L.B.,Schwager, S.L.,Sturrock, E.D.,Acharya, K.R.
Molecular Basis for Multiple Omapatrilat Binding Sites within the ACE C-Domain: Implications for Drug Design.
J. Med. Chem., 61:10141-10154, 2018
Cited by
PubMed Abstract: Omapatrilat was designed as a vasopeptidase inhibitor with dual activity against the zinc metallopeptidases angiotensin-1 converting enzyme (ACE) and neprilysin (NEP). ACE has two homologous catalytic domains (nACE and cACE), which exhibit different substrate specificities. Here, we report high-resolution crystal structures of omapatrilat in complex with nACE and cACE and show omapatrilat has subnanomolar affinity for both domains. The structures show nearly identical binding interactions for omapatrilat in each domain, explaining the lack of domain selectivity. The cACE complex structure revealed an omapatrilat dimer occupying the cavity beyond the S subsite, and this dimer had low micromolar inhibition of nACE and cACE. These results highlight residues beyond the S subsite that could be exploited for domain selective inhibition. In addition, it suggests the possibility of either domain specific allosteric inhibitors that bind exclusively to the nonprime cavity or the potential for targeting specific substrates rather than completely inhibiting the enzyme.
PubMed: 30372620
DOI: 10.1021/acs.jmedchem.8b01309
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (1.37 Å)
Structure validation

227111

數據於2024-11-06公開中

PDB statisticsPDBj update infoContact PDBjnumon